A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly protein
✍ Scribed by Daniel S. Wechsler; Lars D. Engstrom; Brian M. Alexander; David G. Motto; Diane Roulston
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 238 KB
- Volume
- 36
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Rearrangements involving the MLL gene at chromosome band 11q23 are common in infant acute myeloid leukemias (AMLs). We recently encountered an infant patient with rapidly progressive AML whose leukemic cells harbored a previously undescribed MLL rearrangement involving an inversion of 11q [inv(11)(q14q23)]. We used panhandle PCR to determine that this rearrangement juxtaposed the MLL (__M__ixed‐__L__ineage __L__eukemia) gene to the CALM (__C__lathrin __A__ssembly __L__ymphoid __M__yeloid leukemia) gene at 11q14–q21. The CALM protein participates in recruitment of clathrin to internal membrane surfaces, thereby regulating vesicle formation in both endocytosis and intracellular protein transport. Intriguingly, CALM has been identified in other cases of AML as a translocation partner for the AF10 gene, which has independently been found to be an MLL partner in AML. We identified the MLL‐CALM fusion transcript (but not the reciprocal CALM‐MLL transcript) in leukemia cell RNA by RT‐PCR. The predicted 1803 amino acid MLL‐CALM fusion protein includes amino‐terminal MLL domains involved in transcriptional repression, and carboxy‐terminal CALM‐derived clathrin‐binding domains. The genomic breakpoint in MLL is in the 7th intron (within the breakpoint cluster region); the corresponding CALM breakpoint is in the 7th CALM intron. In contrast, breakpoints in CALM‐AF10 translocations lie in the 17th–19th CALM introns (30 kb downstream); also, in these translocations, CALM provides the 5′ end of the fusion transcript. Together with its previously recognized association with AF10 in AML, the identification of CALM as an MLL fusion partner suggests that interference with clathrin‐mediated trafficking pathways may be an underappreciated mechanism in leukemogenesis. © 2002 Wiley‐Liss, Inc.